292 related articles for article (PubMed ID: 25377078)
1. Discovery of Novel SPAK Inhibitors That Block WNK Kinase Signaling to Cation Chloride Transporters.
Kikuchi E; Mori T; Zeniya M; Isobe K; Ishigami-Yuasa M; Fujii S; Kagechika H; Ishihara T; Mizushima T; Sasaki S; Sohara E; Rai T; Uchida S
J Am Soc Nephrol; 2015 Jul; 26(7):1525-36. PubMed ID: 25377078
[TBL] [Abstract][Full Text] [Related]
2. [WNK-SPAK-SLC12A signal cascade is a new therapeutic target for hypertension].
Kikuchi E; Mori T; Uchida S
Nihon Rinsho; 2015 Sep; 73(9):1597-605. PubMed ID: 26394527
[TBL] [Abstract][Full Text] [Related]
3. Impaired phosphorylation of Na(+)-K(+)-2Cl(-) cotransporter by oxidative stress-responsive kinase-1 deficiency manifests hypotension and Bartter-like syndrome.
Lin SH; Yu IS; Jiang ST; Lin SW; Chu P; Chen A; Sytwu HK; Sohara E; Uchida S; Sasaki S; Yang SS
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17538-43. PubMed ID: 21972418
[TBL] [Abstract][Full Text] [Related]
4. Cotransporters, WNKs and hypertension: an update.
Flatman PW
Curr Opin Nephrol Hypertens; 2008 Mar; 17(2):186-92. PubMed ID: 18277153
[TBL] [Abstract][Full Text] [Related]
5. Development of WNK signaling inhibitors as a new class of antihypertensive drugs.
Ishigami-Yuasa M; Watanabe Y; Mori T; Masuno H; Fujii S; Kikuchi E; Uchida S; Kagechika H
Bioorg Med Chem; 2017 Jul; 25(14):3845-3852. PubMed ID: 28566208
[TBL] [Abstract][Full Text] [Related]
6. Chemical library screening for WNK signalling inhibitors using fluorescence correlation spectroscopy.
Mori T; Kikuchi E; Watanabe Y; Fujii S; Ishigami-Yuasa M; Kagechika H; Sohara E; Rai T; Sasaki S; Uchida S
Biochem J; 2013 Nov; 455(3):339-45. PubMed ID: 23981180
[TBL] [Abstract][Full Text] [Related]
7. SPAK-knockout mice manifest Gitelman syndrome and impaired vasoconstriction.
Yang SS; Lo YF; Wu CC; Lin SW; Yeh CJ; Chu P; Sytwu HK; Uchida S; Sasaki S; Lin SH
J Am Soc Nephrol; 2010 Nov; 21(11):1868-77. PubMed ID: 20813865
[TBL] [Abstract][Full Text] [Related]
8. Structural Development of Salicylanilide-Based SPAK Inhibitors as Candidate Antihypertensive Agents.
Fujii S; Kikuchi E; Suzuyama H; Watanabe Y; Ishigami-Yuasa M; Masuno H; Mori T; Isobe K; Uchida S; Kagechika H
ChemMedChem; 2021 Sep; 16(18):2817-2822. PubMed ID: 34109743
[TBL] [Abstract][Full Text] [Related]
9. Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice.
Nishida H; Sohara E; Nomura N; Chiga M; Alessi DR; Rai T; Sasaki S; Uchida S
Hypertension; 2012 Oct; 60(4):981-90. PubMed ID: 22949526
[TBL] [Abstract][Full Text] [Related]
10. Role of the WNK-activated SPAK kinase in regulating blood pressure.
Rafiqi FH; Zuber AM; Glover M; Richardson C; Fleming S; Jovanović S; Jovanović A; O'Shaughnessy KM; Alessi DR
EMBO Mol Med; 2010 Feb; 2(2):63-75. PubMed ID: 20091762
[TBL] [Abstract][Full Text] [Related]
11. Role of SPAK and OSR1 signalling in the regulation of NaCl cotransporters.
Mercier-Zuber A; O'Shaughnessy KM
Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):534-40. PubMed ID: 21610494
[TBL] [Abstract][Full Text] [Related]
12. Functional interactions of the SPAK/OSR1 kinases with their upstream activator WNK1 and downstream substrate NKCC1.
Vitari AC; Thastrup J; Rafiqi FH; Deak M; Morrice NA; Karlsson HK; Alessi DR
Biochem J; 2006 Jul; 397(1):223-31. PubMed ID: 16669787
[TBL] [Abstract][Full Text] [Related]
13. Dietary salt intake regulates WNK3-SPAK-NKCC1 phosphorylation cascade in mouse aorta through angiotensin II.
Zeniya M; Sohara E; Kita S; Iwamoto T; Susa K; Mori T; Oi K; Chiga M; Takahashi D; Yang SS; Lin SH; Rai T; Sasaki S; Uchida S
Hypertension; 2013 Nov; 62(5):872-8. PubMed ID: 24019400
[TBL] [Abstract][Full Text] [Related]
14. Volume sensitivity of cation-Cl- cotransporters is modulated by the interaction of two kinases: Ste20-related proline-alanine-rich kinase and WNK4.
Gagnon KB; England R; Delpire E
Am J Physiol Cell Physiol; 2006 Jan; 290(1):C134-42. PubMed ID: 15930150
[TBL] [Abstract][Full Text] [Related]
15. The WNK-regulated SPAK/OSR1 kinases directly phosphorylate and inhibit the K+-Cl- co-transporters.
de Los Heros P; Alessi DR; Gourlay R; Campbell DG; Deak M; Macartney TJ; Kahle KT; Zhang J
Biochem J; 2014 Mar; 458(3):559-73. PubMed ID: 24393035
[TBL] [Abstract][Full Text] [Related]
16. The WNK-SPAK/OSR1 pathway: master regulator of cation-chloride cotransporters.
Alessi DR; Zhang J; Khanna A; Hochdörfer T; Shang Y; Kahle KT
Sci Signal; 2014 Jul; 7(334):re3. PubMed ID: 25028718
[TBL] [Abstract][Full Text] [Related]
17. SPAK/OSR1 regulate NKCC1 and WNK activity: analysis of WNK isoform interactions and activation by T-loop trans-autophosphorylation.
Thastrup JO; Rafiqi FH; Vitari AC; Pozo-Guisado E; Deak M; Mehellou Y; Alessi DR
Biochem J; 2012 Jan; 441(1):325-37. PubMed ID: 22032326
[TBL] [Abstract][Full Text] [Related]
18. A single binding motif is required for SPAK activation of the Na-K-2Cl cotransporter.
Gagnon KB; England R; Delpire E
Cell Physiol Biochem; 2007; 20(1-4):131-42. PubMed ID: 17595523
[TBL] [Abstract][Full Text] [Related]
19. On the substrate recognition and negative regulation of SPAK, a kinase modulating Na+-K+-2Cl- cotransport activity.
Gagnon KB; Delpire E
Am J Physiol Cell Physiol; 2010 Sep; 299(3):C614-20. PubMed ID: 20463172
[TBL] [Abstract][Full Text] [Related]
20. Novel mechanisms of Na+ retention in obesity: phosphorylation of NKCC2 and regulation of SPAK/OSR1 by AMPK.
Davies M; Fraser SA; Galic S; Choy SW; Katerelos M; Gleich K; Kemp BE; Mount PF; Power DA
Am J Physiol Renal Physiol; 2014 Jul; 307(1):F96-F106. PubMed ID: 24808538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
